



(12) Translation of
European patent specification

(11) NO/EP 3608325 B1

NORWAY

(19) NO

(51) Int Cl.

A61P 31/12 (2006.01)

A61K 45/06 (2006.01)

C07D 471/22 (2006.01)

A61K 31/4985 (2006.01)

A61P 31/18 (2006.01)

C07D 487/14 (2006.01)

A61K 31/529 (2006.01)

A61P 43/00 (2006.01)

C07D 498/18 (2006.01)

A61K 31/553 (2006.01)

C07D 471/18 (2006.01)

Norwegian Industrial Property Office

- (45) Translation Published 2022.09.12
- (80) Date of The European Patent Office Publication of the Granted Patent 2022.07.06
- (86) European Application Nr. 19185121.1
- (86) European Filing Date 2013.12.19
- (87) The European Application's Publication Date 2020.02.12
- (30) Priority 2012.12.21, US, 201261745375 P
2013.03.15, US, 201361788397 P
2013.07.12, US, 201361845803 P
- (84) Designated Contracting States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
Designated Extension States: BA; ME
- (62) Divided application EP3067358, 2013.12.19
- (73) Proprietor Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA
- (72) Inventor HAOLUN, Jin, c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
LAZERWITH, Scott, E., c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
MARTIN, Teresa, Alejandra, Trejo, c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
BACON, Elizabeth, M., c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
COTTELL, Jeromy, J., c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
CAI, Zhenhong, R., c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
PYUN, Hyung-Jung, c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
MORGANELLI, Phillip, Anthony, c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
JI, Mingzhe, 33040 Compton Court, Union City, CA 94587, USA
TAYLOR, James, G., c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
CHEN, Xiaowu, c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, USA

MISH, Michael, R., c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City,
CA 94404, USA
DESAI, Manoj, C., c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City,
CA 94404, USA

(74) Agent or Attorney AWA NORWAY AS, Hoffsvæien 1A, 0275 OSLO, Norge


(54) Title **POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL
USE**

(56) References
Cited: WO-A1-2006/116764
EP-A1- 2 412 709

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse med formel (I):



eller en stereoisomer eller et farmasøytisk akseptabelt salt derav, hvor:

5 X er -O-;

W er -CHZ²-;

Z¹ og Z², tatt sammen, danner -L- hvor L er -C(R^a)₂C(R^a)₂-;

Z⁴ er -CH₂-;


Y¹ og Y² er hver, uavhengig, hydrogen, C₁₋₃-alkyl eller C₁₋₃-halogenalkyl;

10 R¹ er fenyl substituert med ett eller to halogenatomer; og

hver R^a er, uavhengig, hydrogen, halogen, hydroksy eller C₁₋₄-alkyl.



2. Forbindelse ifølge krav 1, med formel (II-A):

2










(II-A)

3. Forbindelse ifølge krav 1, hvor Y^1 og Y^2 er hver uavhengig hydrogen, metyl eller trifluormetyl.
4. Forbindelse ifølge krav 1 eller krav 2, hvor R^1 er substituert med ett
5 halogenatom.
5. Forbindelse ifølge krav 4, hvor R^1 er 4-fluorfenyl eller 2-fluorfenyl.
6. Forbindelse ifølge krav 1 eller krav 2, hvor R^1 er substituert med to halogenatomer.
7. Forbindelse ifølge krav 6, hvor R^1 er 2,4-difluorfenyl, 2,3-difluorfenyl, 2,6-
10 difluorfenyl, 3-fluor-4-klorfenyl, 3,4-difluorfenyl, 2-fluor-4-klorfenyl eller 3,5-difluorfenyl.
8. Forbindelse ifølge krav 7, hvor R^1 er 2,4-difluorfenyl.
9. Forbindelse ifølge krav 1, valgt fra:








3







5

4




5





og



- 5 10. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1-9, eller en stereoisomer eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel bærer, et fortynningsmiddel eller en eksipiens.
11. Farmasøytisk sammensetning ifølge krav 10, ytterligere omfattende ett eller
10 flere ytterligere terapeutiske midler.
12. Farmasøytisk sammensetning ifølge krav 11, hvor det ene eller flere ytterligere terapeutiske midler er et middel mot humant immunsviktvirus.
13. Farmasøytisk sammensetning ifølge krav 12, hvor det ene eller flere ytterligere terapeutiske midler er valgt fra gruppen bestående av humant
15 immunsviktvirus-proteasehemmere, humant immunsviktvirus-ikke-nukleosid-hemmere av revers transkriptase, humant immunsviktvirus-nukleosidhemmere av revers transkriptase, humant immunsviktvirus-nukleotidhemmere av revers transkriptase, og kombinasjoner derav.